Guardian Partners Inc. lifted its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) by 66.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,500 shares of the company’s stock after buying an additional 3,000 shares during the quarter. Guardian Partners Inc.’s holdings in Revolution Medicines were worth $1,539,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of RVMD. Alphabet Inc. bought a new stake in shares of Revolution Medicines during the second quarter worth approximately $551,843,000. Assenagon Asset Management S.A. lifted its holdings in Revolution Medicines by 987.9% in the third quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock valued at $447,710,000 after buying an additional 1,980,699 shares during the period. Bank of America Corp DE bought a new position in Revolution Medicines in the second quarter valued at approximately $184,267,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Revolution Medicines by 82.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 912,335 shares of the company’s stock valued at $170,862,000 after acquiring an additional 411,740 shares during the last quarter. Finally, Deutsche Bank AG bought a new position in Revolution Medicines in the second quarter valued at approximately $166,308,000. Institutional investors and hedge funds own 94.34% of the company’s stock.
Revolution Medicines Price Performance
Shares of Revolution Medicines stock opened at $194.28 on Thursday. The stock’s 50-day moving average is $202.32 and its 200-day moving average is $175.95. Revolution Medicines, Inc. has a one year low of $52.48 and a one year high of $224.31. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period in the prior year, the business earned ($1.31) earnings per share. Research analysts anticipate that Revolution Medicines, Inc. will post -8.93 earnings per share for the current year.
Insiders Place Their Bets
In other Revolution Medicines news, COO Margaret A. Horn sold 4,967 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $989,625.08. Following the completion of the transaction, the chief operating officer owned 149,680 shares of the company’s stock, valued at $29,822,243.20. This represents a 3.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 4,053 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total value of $807,519.72. Following the transaction, the chief financial officer directly owned 119,216 shares of the company’s stock, valued at approximately $23,752,595.84. This trade represents a 3.29% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 290,991 shares of company stock worth $59,422,765 in the last 90 days. Company insiders own 7.60% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts have commented on the stock. Wedbush lifted their target price on shares of Revolution Medicines from $201.00 to $225.00 and gave the stock an “outperform” rating in a report on Thursday, August 27th. Raymond James Financial reissued a “strong-buy” rating and issued a $248.00 price target on shares of Revolution Medicines in a research note on Thursday, August 27th. Morgan Stanley began coverage on Revolution Medicines in a research note on Thursday, September 10th. They issued an “overweight” rating and a $255.00 price target on the stock. TD Cowen restated a “buy” rating and issued a $250.00 price target on shares of Revolution Medicines in a research report on Wednesday. Finally, The Goldman Sachs Group began coverage on Revolution Medicines in a research report on Thursday, September 24th. They set a “buy” rating and a $267.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $242.95.
Read Our Latest Stock Report on RVMD
Revolution Medicines News Summary
Here are the key news stories impacting Revolution Medicines this week:
- Positive Sentiment: Phase 3 trial advanced: Revolution Medicines began treating patients in the RASolve 308 trial, evaluating investigational zoldonrasib alongside pembrolizumab and chemotherapy as a first-line treatment for metastatic RAS G12D non-squamous non-small cell lung cancer. Starting a pivotal trial represents progress toward a potential registration-supporting data set and expands the drug’s commercial opportunity. Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial
- Positive Sentiment: Analyst support remains strong: TD Cowen reaffirmed its “Buy” rating and set a $250 price target, while Brookline Capital Markets maintained a “Buy” rating with a $318 target. Truist Financial also indicated that RVMD’s stock is expected to rise. These targets imply considerable upside based on the referenced trading level. Truist Financial Analyst Expects Revolution Medicines Stock to Rise
- Positive Sentiment: Broader biotech momentum: RVMD was among biotech stocks that advanced during a sector-wide move higher, suggesting favorable industry sentiment also contributed to recent trading interest. Biotech Stocks Move Higher
- Neutral Sentiment: Third-quarter results scheduled: Revolution Medicines will report its third-quarter 2026 financial results after the market closes on November 4, followed by a management webcast. The update may provide new information on cash resources, development spending and clinical progress.
- Neutral Sentiment: Losses remain expected: Brookline projects third-quarter EPS of negative $2.36 and fourth-quarter EPS of negative $1.94, compared with a consensus full-year estimate of negative $8.93. Continued losses are typical for a development-stage biotechnology company but leave RVMD sensitive to earnings, cash-burn and pipeline updates.
Revolution Medicines Profile
Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.
Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.
Read More
- Five stocks we like better than Revolution Medicines
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report).
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
